AvMed

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

<u>Directions</u>: <u>The prescribing physician must sign and clearly print name (preprinted stamps not valid)</u> on this request. All other information may be filled in by office staff; <u>fax to 1-305-671-0200</u>. No additional phone calls will be necessary if all information (<u>including phone and fax #s</u>) on this form is correct. <u>If the information provided is not complete, correct, or legible, the authorization process can be delayed.</u>

Drug Requested: Velsipity[™] (etrasimod)

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.		
Member Name:		
Member AvMed #:	Date of Birth:	
Prescriber Name:		
	Date:	
Office Contact Name:		
Phone Number:	Fax Number:	
DEA OR NPI #:		
DRUG INFORMATION: Authori	ization may be delayed if incomplete.	
Drug Name/Form/Strength:		
Dosing Schedule:	Length of Therapy:	
Diagnosis:	ICD Code, if applicable:	
Weight:	Date:	
immunomodulator (e.g., Dupixent, Entyvi	e of concomitant therapy with more than one biologic io, Humira, Rinvoq, Stelara) prescribed for the same or different gational. Safety and efficacy of these combinations has NOT been	
Quantity Limit: 1 tablet per day		
	elow all that apply. All criteria must be met for approval. To ation, including lab results, diagnostics, and/or chart notes, must be	
☐ Member has a diagnosis of ulcerate	tive colitis	
a monitori nas a diagnosis of alcera	uve contis	

(Continued on next page)

		ember has moderate to severe active disease with inadequate response after a <u>90-day</u> trial of <u>ONE</u> of a following conventional therapies (verified by chart notes or pharmacy paid claims):
		6-mercaptopurine
		aminosalicylates (e.g., mesalamine, balsalazide, olsalazine)
		sulfasalazine
		azathioprine
		corticosteroids (e.g., budesonide, high dose steroids: 40-60 mg of prednisone daily)
	Member meets ONE of the following:	
		Member tried and failed, has a contraindication, or intolerance to <u>BOTH</u> of the following <u>PREFERRED</u> biologics:
		□ <u>ONE</u> of the following adalimumab products:
		☐ Humira [®]
		□ Cyltezo [®]
		□ Hyrimoz [®]
		□ Stelara [®] SQ
		Member has been established on Velsipity [™] for at least 90 days <u>AND</u> prescription claims history indicates <u>at least a 90-day supply of Velsipity was dispensed within the past 130 days</u> (verified by chart notes or pharmacy paid claims)
—— Ted	lica	tion being provided by Specialty Pharmacy – Proprium Ry

**Use of samples to initiate therapy does not meet step edit/ preauthorization criteria. **

*Previous therapies will be verified through pharmacy paid claims or submitted chart notes. *